Dynavax Technologies Corporation Cash Flow Conversion Efficiency
Dynavax Technologies Corporation cash flow conversion efficiency. Based on the latest financial reports, Dynavax Technologies Corporation (DVAX) has a cash flow conversion efficiency ratio of 0.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($33.83 Million) by net assets ($534.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Dynavax Technologies Corporation (2002–2024)
Cash flow conversion efficiency of Dynavax Technologies Corporation from 2002 to 2024. This chart illustrates how Dynavax Technologies Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DVAX share price today for real-time trading data and today's change.
Dynavax Technologies Corporation Cash Flow Conversion Ratio Explained
Dynavax Technologies Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dynavax Technologies Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dynavax Technologies Corporation ranked by their cash flow conversion efficiency. Also see DVAX market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ARMOUR Residential REIT Inc
NYSE:ARR
|
0.081x |
|
Sunway Real Estate Investment Trust
KLSE:5176
|
0.015x |
|
Mayora Indah Tbk
JK:MYOR
|
0.058x |
|
Iluka Resources Ltd
AU:ILU
|
-0.039x |
|
Semapa
LS:SEM
|
0.059x |
|
A.F.P. Provida
SN:PROVIDA
|
0.022x |
|
NCAB Group
ST:NCAB
|
0.199x |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Dynavax Technologies Corporation (2002–2024)
The table below shows the annual cash flow conversion efficiency of Dynavax Technologies Corporation from 2002 to 2024. Review Dynavax Technologies Corporation free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $596.80 Million | $66.51 Million | 0.111x | -31.06% |
| 2023-12-31 | $622.07 Million | $100.56 Million | 0.162x | +49.76% |
| 2022-12-31 | $581.01 Million | $62.72 Million | 0.108x | -92.85% |
| 2021-12-31 | $222.37 Million | $335.53 Million | 1.509x | +196.00% |
| 2020-12-31 | $58.69 Million | $-92.25 Million | -1.572x | +89.25% |
| 2019-12-31 | $8.29 Million | $-121.25 Million | -14.626x | -602.51% |
| 2018-12-31 | $63.06 Million | $-131.30 Million | -2.082x | -435.95% |
| 2017-12-31 | $199.55 Million | $-77.52 Million | -0.388x | +67.63% |
| 2016-12-31 | $89.20 Million | $-107.05 Million | -1.200x | -142.56% |
| 2015-12-31 | $187.08 Million | $-92.56 Million | -0.495x | +32.58% |
| 2014-12-31 | $100.48 Million | $-73.74 Million | -0.734x | -133.00% |
| 2013-12-31 | $186.29 Million | $-58.67 Million | -0.315x | +17.45% |
| 2012-12-31 | $114.83 Million | $-43.81 Million | -0.382x | +19.12% |
| 2011-12-31 | $99.88 Million | $-47.12 Million | -0.472x | +52.15% |
| 2010-12-31 | $52.11 Million | $-51.37 Million | -0.986x | +81.27% |
| 2009-12-31 | $6.38 Million | $-33.55 Million | -5.262x | -399.07% |
| 2008-12-31 | $16.16 Million | $-17.04 Million | -1.054x | -28.81% |
| 2007-12-31 | $39.13 Million | $-32.03 Million | -0.819x | -73.81% |
| 2006-12-31 | $79.07 Million | $-37.24 Million | -0.471x | -53.22% |
| 2005-12-31 | $74.36 Million | $-22.86 Million | -0.307x | -151.02% |
| 2004-12-31 | $59.88 Million | $-7.33 Million | -0.122x | -148.62% |
| 2003-12-31 | $-57.20 Million | $-14.41 Million | 0.252x | -0.60% |
| 2002-12-31 | $-56.37 Million | $-14.28 Million | 0.253x | -- |
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more